Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Lung Cancer in Peru.
Ruiz R, Galvez-Nino M, Poquioma E, Limache-García A, Amorin E, Olivera M, Valdiviezo N, Trejo JM, Heredia A, Sarria G, Aguilar A, Raez L, Neciosup SP, Gomez HL, Payet E, Mas L. Ruiz R, et al. Among authors: valdiviezo n. J Thorac Oncol. 2020 Jun;15(6):891-898. doi: 10.1016/j.jtho.2020.01.018. J Thorac Oncol. 2020. PMID: 32471564 Free article. No abstract available.
Epidemiology of thymic epithelial tumors: 22-years experience from a single-institution.
Rioja P, Ruiz R, Galvez-Nino M, Lozano S, Valdiviezo N, Olivera M, Cabero O, Guillen ME, De La Guerra A, Amorin E, Barrionuevo C, Mas L. Rioja P, et al. Among authors: valdiviezo n. Thorac Cancer. 2021 Feb;12(4):420-425. doi: 10.1111/1759-7714.13760. Epub 2020 Dec 23. Thorac Cancer. 2021. PMID: 33356008 Free PMC article.
Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study.
Valdiviezo N, Alcarraz C, Castro D, Salas R, Begazo-Mollo V, Galvez-Villanueva M, Medina Aguirre L, Garcia-León E, Quispe-Santivañez I, Cornejo-Raymundo C, Paz-Cornejo E, Sanchez-Vilela L, Bermudez-Alfaro V, Vargas-Nina JC, Pérez-Ramos C, Meza-Hoces A, Valdez Barreto PR, Huaringa-Leiva R, Muro-Cieza J, Aguilar-Vásquez V, Cuenca EY, Neciosup-Delgado S, Poma-Nieto N, Chavez-Gavino S, Fernandez-Rosas L, Araujo JM, Payet E, Gomez HL. Valdiviezo N, et al. Cancer Manag Res. 2022 Mar 8;14:1075-1085. doi: 10.2147/CMAR.S350038. eCollection 2022. Cancer Manag Res. 2022. PMID: 35300062 Free PMC article.
Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.
Otoya I, Valdiviezo N, Morante Z, Calle C, Ferreyra Y, Huarcaya-Chombo N, Polo-Mendoza G, Castañeda C, Vidaurre T, Neciosup SP, Calderón MJ, Gomez HL. Otoya I, et al. Among authors: valdiviezo n. Int J Breast Cancer. 2024 Jun 22;2024:9551710. doi: 10.1155/2024/9551710. eCollection 2024. Int J Breast Cancer. 2024. PMID: 38962673 Free PMC article.
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. Jänne PA, et al. Among authors: valdiviezo n. J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2. J Clin Oncol. 2024. PMID: 38042525 Free PMC article. Clinical Trial.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ, Toita T, Wu X, Vázquez Limón JC, Tarnawski R, Mandai M, Shapira-Frommer R, Mahantshetty U, Del Pilar Estevez-Diz M, Zhou Q, Limaye S, Godinez FJR, Oppermann Kussler C, Varga S, Valdiviezo N, Aoki D, Leiva M, Lee JY, Sulay R, Kreynina Y, Cheng WF, Rey F, Rong Y, Ke G, Wildsmith S, Lloyd A, Dry H, Tablante Nunes A, Mayadev J. Monk BJ, et al. Among authors: valdiviezo n. Lancet Oncol. 2023 Dec;24(12):1334-1348. doi: 10.1016/S1470-2045(23)00479-5. Lancet Oncol. 2023. PMID: 38039991 Clinical Trial.
26 results